

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252741 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 47/38* (2006.01)
A61K 9/28 (2006.01) *A61K 31/473* (2006.01)
A61K 9/20 (2006.01) *A61P 25/14* (2006.01)
A61K 47/10 (2017.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/US2021/036778

(22) International Filing Date:

10 June 2021 (10.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/037,369	10 June 2020 (10.06.2020)	US
63/037,953	11 June 2020 (11.06.2020)	US
63/044,451	26 June 2020 (26.06.2020)	US

(71) Applicant: **AUSPEX PHARMACEUTICALS, INC.**
[US/US]; 400 Interpace Parkway, Parsippany, NJ 07054 (US).

(72) Inventors: **SHAH, Parag**; 1090 Horsham Road, North Wales, PA 19454 (US). **JOSHI, Mayank**; 2518 Princeton Ct., Weston, FL 33327 (US). **PATTANAYEK, Soumen**; 1090 Horsham Road, North Wales, PA 19454 (US). **PATEL, Divyang**; 1090 Horsham Road, North Wales, PA 19454 (US). **PANDITA, Sandeep**; 400 Interpace Parkway, Parsippany, NJ 07054 (US).

(74) Agent: **LODISE, Stephanie, A.**; Baker & Hostetler LLP, Cira Centre, 12th Floor, 2929 Arch Street, Philadelphia, PA 19104 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF

FIG. 1



(57) Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once- daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.



WO 2021/252741 A1